Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Gene Therapy00:59

Gene Therapy

25.8K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of invasive fungal infections in 358 children undergoing allogeneic haematopoietic stem cell transplantation: A prospective UK study.

British journal of haematology·2026
Same author

Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease.

Journal of human immunity·2026
Same author

Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for 'off-the-shelf' immunotherapy.

Haematologica·2025
Same author

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.

The New England journal of medicine·2025
Same author

Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group.

Transplantation and cellular therapy·2025
Same author

Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.

Leukemia·2025

Related Experiment Video

Updated: Sep 6, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

422

Genome-Edited T Cell Therapies.

Giorgio Ottaviano1, Waseem Qasim1

  • 1Infection, Immunity & Inflammation Department, UCL Great Ormond Street Institute of Child Health, University College London Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.

Hematology/Oncology Clinics of North America
|June 30, 2022
PubMed
Summary
This summary is machine-generated.

Universal donor chimeric antigen receptor (CAR) T-cells are being developed for wider access to cancer therapies. Advanced genome editing, including CRISPR technology, shows promise for enhancing these off-the-shelf cell therapies against hematological malignancies.

Keywords:
Base editorCRISPR/Cas9Chimeric antigen receptorCytidine deaminationGenome editingT cell therapies

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.3K
Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

13.3K

Related Experiment Videos

Last Updated: Sep 6, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

422
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.3K
Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

13.3K

Area of Science:

  • Oncology
  • Immunotherapy
  • Gene Editing

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy is under investigation for treating malignancies.
  • Allogeneic 'universal donor' CAR-T cells offer potential for pre-manufactured, off-the-shelf treatments.
  • Existing CAR-T therapies face challenges including human leukocyte antigen (HLA) barriers.

Purpose of the Study:

  • To explore the potential of universal donor CAR-T cells for improved accessibility.
  • To review genome-editing platforms used to overcome HLA barriers in CAR-T cell therapy.
  • To highlight the prospects of CRISPR-based systems for enhanced cellular immunotherapies.

Main Methods:

  • Review of genome-editing platforms for CAR-T cell generation.
  • Analysis of early clinical applications of universal CAR-T cells.
  • Examination of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technologies.

Main Results:

  • Universal donor CAR-T cell therapy has been applied in pediatric and adult B cell malignancies.
  • Various genome-editing techniques have been employed to address HLA compatibility.
  • CRISPR and related technologies present opportunities for advanced CAR-T cell therapies.

Conclusions:

  • Universal donor CAR-T cells could broaden access to cancer immunotherapy.
  • Genome editing is crucial for developing effective allogeneic CAR-T cell products.
  • CRISPR technology holds significant promise for future hematological cancer treatments.